FIELD: clinical hematology.
SUBSTANCE: invention, in particular, is dealing with using activated blood coagulation factor VII (VIIa) when treating extensive bloodings caused by thrombolytic/fibrinolytic therapy, including intracranial hemorrhages, and to corresponding treatment method.
EFFECT: obtained desired result at low undesired effect occurrence in patients suffering from indicated bloodings.
10 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTICS OF THROMBOEMBOLIC VEIN DISEASES BY DETERMINATION OF CONTENT OF D-DIMERS AND SOLUBLE FIBRIN | 2007 |
|
RU2475760C2 |
| COMPOSITIONS FOR ANTIFIBRINOLYTIC TREATMENT | 2008 |
|
RU2453337C2 |
| METHOD OF ACUTE MYOCARDIAL INFARCTION TREATMENT | 2008 |
|
RU2365380C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VII POLYPEPTIDES AND FACTOR XI POLYPEPTIDES | 2002 |
|
RU2298416C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VII POLYPEPTIDES AND PAI-1 POLYPEPTIDES | 2002 |
|
RU2304980C2 |
| COMBINATION OF THROMBOLYTICALLY ACTIVE PROTEINS AND ANTICOAGULANTS | 1995 |
|
RU2166326C2 |
| METHOD FOR QUANTITATIVE DETERMINATION OF SOLUBLE FIBRIN | 2001 |
|
RU2310200C2 |
| METHODS OF TREATING TRACHEAL, BRONCHIAL OR ALVEOLAR HAEMORRHAGE OR HEMOPTYSIS | 2005 |
|
RU2396086C2 |
| COMBINED APPLICATION OF FACTOR VII POLYPEPTIDES AND FACTOR VIII POLYPEPTIDES | 2002 |
|
RU2311923C2 |
| THROMBOLYTIC AGENTS | 1995 |
|
RU2142799C1 |
